Literature DB >> 25589564

Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data.

Rachel Sacks-Davis1, Emma McBryde2, Jason Grebely3, Margaret Hellard4, Peter Vickerman5.   

Abstract

Hepatitis C virus (HCV) reinfection rates are probably underestimated due to reinfection episodes occurring between study visits. A Markov model of HCV reinfection and spontaneous clearance was fitted to empirical data. Bayesian post-estimation was used to project reinfection rates, reinfection spontaneous clearance probability and duration of reinfection. Uniform prior probability distributions were assumed for reinfection rate (more than 0), spontaneous clearance probability (0-1) and duration (0.25-6.00 months). Model estimates were 104 per 100 person-years (95% CrI: 21-344), 0.84 (95% CrI: 0.59-0.98) and 1.3 months (95% CrI: 0.3-4.1) for reinfection rate, spontaneous clearance probability and duration, respectively. Simulation studies were used to assess model validity, demonstrating that the Bayesian model estimates provided useful information about the possible sources and magnitude of bias in epidemiological estimates of reinfection rates, probability of reinfection clearance and duration or reinfection. The quality of the Bayesian estimates improved for larger samples and shorter test intervals. Uncertainty in model estimates notwithstanding, findings suggest that HCV reinfections frequently and quickly result in spontaneous clearance, with many reinfection events going unobserved.
© 2015 The Author(s) Published by the Royal Society. All rights reserved.

Entities:  

Keywords:  Monte Carlo Markov chain; epidemiology; hepatitis C infection

Mesh:

Substances:

Year:  2015        PMID: 25589564      PMCID: PMC4345484          DOI: 10.1098/rsif.2014.1197

Source DB:  PubMed          Journal:  J R Soc Interface        ISSN: 1742-5662            Impact factor:   4.118


  41 in total

Review 1.  Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies.

Authors:  J M Micallef; J M Kaldor; G J Dore
Journal:  J Viral Hepat       Date:  2006-01       Impact factor: 3.728

2.  Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users.

Authors:  J Amin; M G Law; J Micallef; M Jauncey; I Van Beek; J M Kaldor; G J Dore
Journal:  Epidemiol Infect       Date:  2006-05-17       Impact factor: 2.451

Review 3.  Molecular diagnostics of hepatitis C virus infection: a systematic review.

Authors:  John D Scott; David R Gretch
Journal:  JAMA       Date:  2007-02-21       Impact factor: 56.272

4.  Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model.

Authors:  Alfred M Prince; Betsy Brotman; Dong-Hun Lee; Wolfram Pfahler; Nancy Tricoche; Linda Andrus; Mohamed T Shata
Journal:  J Infect Dis       Date:  2005-10-06       Impact factor: 5.226

5.  Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia.

Authors:  E R Miller; M E Hellard; S Bowden; M Bharadwaj; C K Aitken
Journal:  J Infect       Date:  2009-03-27       Impact factor: 6.072

6.  High incidence of hepatitis C virus reinfection in a cohort of injecting drug users.

Authors:  Campbell Kynoch Aitken; Jennifer Lewis; Samantha Lilly Tracy; Timothy Spelman; David Scott Bowden; Mandvi Bharadwaj; Heidi Drummer; Margaret Hellard
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

7.  A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus.

Authors:  Sue L Currie; James C Ryan; Daniel Tracy; Teresa L Wright; Sally George; Rosemary McQuaid; Michael Kim; Hui Shen; Alexander Monto
Journal:  Drug Alcohol Depend       Date:  2007-10-30       Impact factor: 4.492

8.  Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users.

Authors:  Jason Grebely; Jesse D Raffa; Calvin Lai; Mel Krajden; Brian Conway; Mark W Tyndall
Journal:  Can J Gastroenterol       Date:  2007-07       Impact factor: 3.522

9.  The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy.

Authors:  J W Mosley; E A Operskalski; L H Tobler; Z J Buskell; W W Andrews; B Phelps; J Dockter; C Giachetti; L B Seeff; M P Busch
Journal:  J Viral Hepat       Date:  2008-02       Impact factor: 3.728

10.  High incidence of hepatitis C virus reinfection within a cohort of injecting drug users.

Authors:  J M Micallef; V Macdonald; M Jauncey; J Amin; W Rawlinson; I van Beek; J M Kaldor; P A White; G J Dore
Journal:  J Viral Hepat       Date:  2007-06       Impact factor: 3.728

View more
  7 in total

Review 1.  Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges.

Authors:  Nick Scott; Margaret Hellard; Emma Sue McBryde
Journal:  Virulence       Date:  2015-08-25       Impact factor: 5.882

2.  Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.

Authors:  Hannah Fraser; Natasha K Martin; Henrikki Brummer-Korvenkontio; Patrizia Carrieri; Olav Dalgard; John Dillon; David Goldberg; Sharon Hutchinson; Marie Jauffret-Roustide; Martin Kåberg; Amy A Matser; Mojca Matičič; Havard Midgard; Viktor Mravcik; Anne Øvrehus; Maria Prins; Jens Reimer; Geert Robaeys; Bernd Schulte; Daniela K van Santen; Ruth Zimmermann; Peter Vickerman; Matthew Hickman
Journal:  J Hepatol       Date:  2018-01-08       Impact factor: 25.083

3.  The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis.

Authors:  Peng Huang; Yan Wang; Ming Yue; Zhijun Ge; Xueshan Xia; Andre J Jeyarajan; Jacinta A Holmes; Rongbin Yu; Chuanwu Zhu; Sheng Yang; Wenyu Lin; Raymond T Chung
Journal:  Liver Int       Date:  2021-06-16       Impact factor: 8.754

4.  Prevalence of mixed genotype hepatitis C virus infections in the UK as determined by genotype-specific PCR and deep sequencing.

Authors:  A L McNaughton; V B Sreenu; G Wilkie; R Gunson; K Templeton; E C M Leitch
Journal:  J Viral Hepat       Date:  2018-02-21       Impact factor: 3.728

5.  Combination interventions for Hepatitis C and Cirrhosis reduction among people who inject drugs: An agent-based, networked population simulation experiment.

Authors:  Bilal Khan; Ian Duncan; Mohamad Saad; Daniel Schaefer; Ashly Jordan; Daniel Smith; Alan Neaigus; Don Des Jarlais; Holly Hagan; Kirk Dombrowski
Journal:  PLoS One       Date:  2018-11-29       Impact factor: 3.240

6.  Spatiotemporal Reconstruction of the Introduction of Hepatitis C Virus into Scotland and Its Subsequent Regional Transmission.

Authors:  Anna L McNaughton; Iain Dugald Cameron; Elizabeth B Wignall-Fleming; Roman Biek; John McLauchlan; Rory N Gunson; Kate Templeton; Harriet Mei-Lin Tan; E Carol McWilliam Leitch
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

7.  Quantitative Analysis of Axonal Branch Dynamics in the Developing Nervous System.

Authors:  Kelsey Chalmers; Elizabeth M Kita; Ethan K Scott; Geoffrey J Goodhill
Journal:  PLoS Comput Biol       Date:  2016-03-21       Impact factor: 4.475

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.